Sociedad Americana de Hirudoterapia

Sarah M.

Venous Congestion in DIEP Flap

52 · Boston, Massachusetts202510Registros médicos verificados
Salvamento de colgajo postquirúrgicoRecuperación quirúrgica

Nunca pensé que dejaría voluntariamente que unas sanguijuelas se alimentaran de mí, pero cuando la elección era entre eso o perder mi reconstrucción, la decisión se tomó sola muy rápidamente.

Sarah M.

Sarah M., a 52-year-old marketing executive from Boston, shares her experience with medicinal leech therapy following complications from breast reconstruction surgery. Her story illustrates both the challenges of post-surgical complications and the potential of leech therapy as a salvage treatment.

Background: The Cancer Diagnosis

In March 2024, Sarah discovered a lump — biopsy revealed invasive ductal carcinoma, Stage IIA (2.3 cm, ER-positive, HER2-negative). She chose bilateral mastectomy with immediate DIEP flap reconstruction, followed by chemotherapy and hormonal therapy.

I was overwhelmed with information. Given my family history and the lymph node involvement, I chose bilateral mastectomy with immediate reconstruction.

patient-stories.stories.post-surgical-recovery.sections.background.quoteAttribution

patient-stories.stories.post-surgical-recovery.sections.treatment.title

patient-stories.stories.post-surgical-recovery.sections.treatment.content

patient-stories.stories.post-surgical-recovery.sections.treatment.quote

patient-stories.stories.post-surgical-recovery.sections.treatment.quoteAttribution

patient-stories.stories.post-surgical-recovery.sections.experience.title

patient-stories.stories.post-surgical-recovery.sections.experience.content

patient-stories.stories.post-surgical-recovery.sections.experience.quote

patient-stories.stories.post-surgical-recovery.sections.experience.quoteAttribution

patient-stories.stories.post-surgical-recovery.sections.challenges.title

patient-stories.stories.post-surgical-recovery.sections.challenges.content

patient-stories.stories.post-surgical-recovery.sections.challenges.quote

patient-stories.stories.post-surgical-recovery.sections.challenges.quoteAttribution

patient-stories.stories.post-surgical-recovery.sections.outcomes.title

patient-stories.stories.post-surgical-recovery.sections.outcomes.content

patient-stories.stories.post-surgical-recovery.sections.outcomes.quote

patient-stories.stories.post-surgical-recovery.sections.outcomes.quoteAttribution

patient-stories.stories.post-surgical-recovery.sections.reflections.title

patient-stories.stories.post-surgical-recovery.sections.reflections.content

patient-stories.stories.post-surgical-recovery.sections.reflections.quote

patient-stories.stories.post-surgical-recovery.sections.reflections.quoteAttribution

Key Outcomes

Flap salvaged — avoided additional surgery
FDA-cleared indication for medicinal leeches
Normal color and blood flow restored by day 5
Excellent cosmetic result at 3 months
Full range of motion restored
No long-term complications from leech therapy

Perspectiva médica

Médico tratante

Dr. Jennifer Walsh, MD

Plastic and Reconstructive Surgery

Sarah's case represents a typical successful application of medicinal leech therapy for venous congestion in a DIEP flap. Key success factors: early recognition within 24 hours, prompt initiation, adequate arterial inflow, proper antibiotic prophylaxis and transfusion management. Leech therapy is our first-line treatment for venous congestion when surgical revision isn't immediately available.

Aviso médico

Los resultados individuales varían. Estas historias representan experiencias personales y no son garantía de resultados. La hirudoterapia requiere supervisión médica adecuada. Consulte a un profesional de salud calificado antes de iniciar cualquier tratamiento.

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.